The current research evaluated metabolic side eff ects in inpatients (N = 271) using atypical antipsychotic medications in a psychiatric hospital in Turkey between June and December 2016. Data were collected via an information form created after reviewing the literature at the time of patients' hospitalization and discharge. According to the analysis, 73.8% of patients stated they experienced side eff ects from antipsychotic medications and 20.7% of patients experienced weight gain. A statistical diff erence was detected among body mass index, waist circumference, diastolic blood pressure, and heart rate during patient hospitalization and discharge. Patients using atypical antipsychotic medications gained weight, had increased cardiovascular risk, and experienced adverse eff ects on their physical health during hospitalization. Mental health nurses should inform patients of medication eff ects and possible side eff ects, monitor side eff ects, and teach patients how to manage metabolic side eff ects.
A ntipsychotic medications have been in use for more than 50 years for the treatment of many mental disorders, especially schizophrenia and other psychotic disorders (Jones et al., 2006; Yagcioglu & Ertugrul, 2011) . Atypical antipsychotic agents are as effective as typical antipsychotic agents for the treatment of psychotic symptoms and are more effective for negative, cognitive, and depressive symptoms (Jones et al., 2006) . In addition, atypical antipsychotic agents cause less extrapyramidal side effects than typical antipsychotic agents (Jones et al., 2006) .
In addition to the therapeutic effects of atypical antipsychotic agents, these medications also bind to receptors causing metabolic side effects such as weight gain, abdominal obesity, abnormalities in glucose and lipid mechanisms, and increases in blood pressure (Nasrallah, 2008) . Weight gain in patients using atypical antipsychotic medications during treatment is a common problem. Weight gain is associated particularly with abdominal fat deposits, insulin resistance, hyperlipidemia, and hypertension (Demirel, Demirel, Ugur, & Kadak, 2013) . Obesity can cause early cardiovascular risks and development of diabetes (Demirel, Demirel, & Ugur, 2015) . Among atypical antipsychotic medications, clozapine, olanzapine, quetiapine, and risperidone cause the most weight gain (Demirel et al., 2015; Mete & Unsal, 2004; Yüksel & Sayin, 2006) . In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) observational randomized controlled trial, patients using antipsychotic agents were monitored for 18 months and their body weights were found to increase by 4.3 kg, 0.36 kg, and 0.59 kg with the use of olanzapine, risperidone, and quetiapine, respectively . Olanzapine had the most adverse metabolic effects and highest discontinuation rate due to intolerance in the CATIE study (Lieberman & Stroup, 2011) . Therefore, patients using these medications are at a higher risk for metabolic syndrome than the normal population.
Obesity and metabolic syndrome not only negatively affects patients' quality of life (Yilmaz & Buzlu, 2006) , but also shortens their lifespan, as it is a risk factor for cardiovascular diseases (Demirel et al., 2015) . Cardiovascular diseases, diabetes, metabolic syndrome, and obesity are more common among patients taking atypical antipsychotic agents than other populations because of the metabolic side effects caused by malnutrition, smoking, and lack of exercise, which shortens these patients' lifespans by 15 to 20 years (Bressington et al., 2014; Farrelly et al., 2014; Mete & Ünsal, 2004; Nasrallah, 2008) .
The CATIE study showed that weight gain and physical illnesses associated with atypical antipsychotic medications were higher in patients who took atypical antipsychotic agents. Goff et al. (2005) compared 10-year risk for coronary heart disease (CHD) between patients with schizophrenia who participated in the CATIE and Framingham studies with age-, race-and gender-matched controls from the National Health and Nutrition Examination Survey (NHANES) III. The study found that cardiac mortality in patients with schizophrenia was higher than the control group according to smoking, body mass index (BMI), diabetes, hypertension, and high-density lipoprotein (HDL) cholesterol (Goff et al., 2005) . The relative risk factors, such as specifi c antipsychotic agents, diet, exercise, and quality of medical care, remain unclarifi ed.
According to the CATIE study, 74% of patients who used antipsychotic agents discontinued their initial study medication before 18 months . Causes of treatment nonadherence include factors related to patients themselves, health personnel, patients' relatives, diseases, and treatment regimen. The main cause of treatment regimen nonadherence is side effects caused by the medications. Patients' adherence to antipsychotic treatment is reduced by medicinal side effects (Haddad, Brain, & Scott, 2014) . Dibonaventura, Gabriel, Dupclay, Gupta, and Kim (2012) reported a relationship between poor adherence and side effects in patients with schizophrenia. When patients discontinue their medications because of side effects, they often remain in the hospital (Demirel et al., 2015; Yilmaz & Buzlu, 2006) . Continued hospitalization makes their illness chronic; this situation causes exhaustion for patients, patients' relatives, and health care staff, and increases the cost for health care services (Dikeç & Kutlu, 2015) .
Mental health and psychiatric nurses should collaborate with patients to manage medicinal side effects and help them cope using psychosocial interventions. Patients stated that they stopped taking their medications not because of side effects, but because they did not know how to cope with these effects. Therefore, having no knowledge about how to cope with side effects affects patients' adherence to treatment more than the actual side effects experienced (Haddad et al., 2014) .
Antipsychotic agents alone are not effective in treatment of many psychiatric disorders. These drugs must be combined with other psychosocial interventions. Swartz et al. (2007) evaluated the effectiveness of atypical antipsychotic medications on the psychosocial functioning of patients with chronic schizophrenia in the CATIE study. They found no signifi cant differences among treatment groups in the amount of change in the Quality of Life Scale total score or subscale scores at 6, 12, or 18 months. They concluded that more substantial improvements would require more intensive adjunctive psychosocial rehabilitation (Swartz et al., 2007) .
According to the schizophrenia Patient Outcomes Research Team (PORT), there are eight evidencebased treatment recommendations: (a) assertive community treatment, (b) supported employment, (c) cognitive-behavioral therapy, (d) family-based services, (e) token economy, (f) skills training, (g) psychosocial interventions for alcohol and substance use disorders, and (h) psychosocial interventions for weight management (Dixon et al., 2009) . These interventions are important to patients' physical health, treatment adherence, insight, and cognitive functions. Therefore, the prevention of metabolic effects caused by atypical antipsychotic agents requires signifi cant intervention from mental health nurses who spend more time with patients, including provision of follow up regarding metabolic parameters, encouragement to live a healthy life, early diagnosis of side effects, and psychoeducation about expected benefi ts and possible side effects from the treatment through suitable psychosocial interventions and cooperating with patients to increase adherence to treatment (Demirel et al., 2015; Yilmaz & Buzlu, 2006) . Patients' mental and physical health must be evaluated as a whole, and patients must be cared for in accordance with their needs. The purpose of the current study was to determine metabolic side effects of atypical antipsychotic medications experienced by inpatients during hospitalization at a regional psychiatric hospital in Turkey.
METHOD Study Aim
The aim of the current study was to compare the metabolic values of patients using atypical antipsychotic agents at the time of hospitalization and discharge and evaluate any metabolic side effects.
Study Design
The study included observational and descriptive research.
Study Sample
The study population comprised inpatients from adult psychiatric services of a regional psychiatric hospital in Turkey between June and December 2016. These inpatients took clozapine, olanzapine, quetiapine, and risperidone parenterally and orally. Patients using only these medications were included in the study because the literature states that they cause the most weight gain and metabolic side effects (Demirel et al., 2015; Mete & Ünsal, 2004; Yüksel & Sayin, 2006) .
The inclusion criteria for the study were: age 18 or older; diagnosed with mental disorders based on diagnosis criteria in the fi fth edition of the Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, 2013); using atypical antipsychotic medication for at least 3 months; taking clozapine, olanzapine, quetiapine, or risperidone parenterally or orally; being an inpatient at the time of data collection; and volunteering as either the patient or their legal guardian to take part in the study. Study analysis was based on 271 patient questionnaires.
Measurement
An information form was prepared after reviewing the literature (Bressington et al., 2014; Bressington, Mui, Wells, et al., 2016; Güveli et al., 2011; Öyekçin, 2009) , which was completed by researchers and patients. No standardized scale was used in the current study because of lack of validity and reliability among Turkish adult patients with mental disorders.
Information Form. Prepared by the researchers, this form comprised 25 open-and closed-ended questions to determine patients' sociodemographic characteristics, eating and exercise habits, and metabolic values. Researchers collected patients' sociodemographic characteristics from self-reporting and measured the other parameters. Researchers measured patients' height, weight, blood pressure, pulse rate, and waist circumference and found related parameters from patient fi les or records. All metabolic parameters were measured at the time of hospitalization and discharge.
Study Process
From the routine tests performed at the time patients were admitted to the psychiatry inpatient clinic, the results of total cholesterol (TC), lowdensity lipoprotein (LDL) cholesterol, HDL cholesterol, triglyceride (TG), fasting blood glucose (FBG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and creatinine (Cr) were obtained. These samples were obtained on an empty stomach. Height was measured on the second day of hospitalization and fasting weight and waist circumference (WC) were measured in the morning. After resting for 15 minutes, blood pressure (BP) and heart rate (HR) were measured. On the day of discharge, patients were weighed (fasting in the morning); their WCs were measured; and, again after a 15-minute rest, their BPs and HRs were measured. BMI was calculated as weight in kilograms divided by height in meters squared.
Patients' identifi cation details were not taken in the study and coding was used on the questionnaires to avoid confusion at the time of admission and discharge. Coding used patients' initials and the last two numbers of their date of birth.
The mean hospitalization period of the participating patients was 28.67 days. Research data were collected by a mental health nurse working in the department hosting the current research study with a postgraduate degree in the fi eld (G.B.U.) and 8 years of experience working in the child and adolescent psychiatry ...The prevention of metabolic eff ects caused by atypical antipsychotic agents requires signifi cant intervention from mental health nurses... department. The mental health nurse used the same and new calibrated scale and measuring tape for data collection.
Ethical Considerations
Research ethics committee approval was obtained from Izmir Katip Celebi University Non-Invasive Clinics Research Ethics Committee. Approval was also given by the hospital administration where the study was performed.
Statistical Analysis
Data were evaluated using descriptive statistics (e.g., median [SD] , range, percentage) and test of normality, and paired sample t tests were used to compare variables. Results were evaluated at the 95% confi dence interval (CI) and p < 0.05 significance levels.
RESULTS
Participant sociodemographic characteristics are provided in Table 1 . Of 271 patients, mean age was 38.25 (SD = 13.55 years), and 47.6% were women and 52.4% were men. In addition, 44.6% of participants were primary school graduates, 68.6% were unemployed, 44.3% self-identifi ed as middle class, 44.3% self-identifi ed as low class/ poor, and 80.8% received social security.
Participant characteristics regarding mental disorders, medication, and physical habits are provided in Table 2 . The mean disease period was 115.2 months (SD = 110.34 months), mean treatment period was 99.33 months (SD = 102.26 months), and mean number of hospitalizations was 5.94 (SD = 7.02).
In response to the question regarding whether they took their medications regularly, 39.9% stated they always took their medication on time, 28.4% stated they often took their medication, and 22.1% stated they sometimes took their medication. Side effects were identifi ed by 73.8% of patients and included weight gain (20.7%), dizziness (18.1%), increased sleep periods (11.2%), insomnia (8.5%), athetosis (5.6%), constipation (3%), and muscle contraction (1.8%). In addition, 4.9% of patients had side effects such as nausea, tachycardia, suicidality, skin eruption, xerostomia, and dysmnesia ( Table 2) .
The questionnaire revealed that 76% of patients had main meals three times per day and 67.9% had snacks in addition to main meals. Furthermore, 31.7% of patients exercised with a duration of 7.79 minutes (SD = 14.6 minutes) per day, 25.8% exercised on their own as opposed to with a trainer or nurse at the clinic, and 19.9% exercised 4 to 6 times per week ( Table 2) .
Patients' laboratory values at the time of hospitalization are shown in Table 3 . Differences in physical measurement fi ndings/values between hospitalization and discharge were calculated using paired samples t test.
BMIs, WCs, average diastolic blood pressure (DBP), and HRs at the time of hospitalization were signifi cantly different from the values obtained at discharge (p < 0.001) ( Table 4) . Moreover, WCs and BMIs of female and male patients were signifi cantly different between hospitalization and discharge (p < 0.001) ( Table 4) .
DISCUSSION
The aim of the current study was to determine metabolic side effects from atypical antipsychotic medications. More than one half of participants were male and most were primary school graduates. As the majority of patients were primary school graduates and most mental disorders started during adolescence, their school life may have been negatively affected by this situation. It was also found that more than one half of patients were unemployed, and most patients stated they were middle or low class and received Social Security. Mean disease duration was 9.6 years, mean treatment duration was 8.27 years, and mean number of hospitalizations was 5.94. Mean disease duration, treatment duration, and number of hospitalizations were similar, leading the current authors to believe patients had diffi culty accepting their illness and adhering to treatment. Treatment adherence diffi culties could be caused by medication side effects. Thus, when patients were asked about adherence to treatment, only 39.9% stated they took their medications regularly.
In the current study, most patients experienced side effects from their medications, with the most common side effect being weight gain, which is the most signifi cant side effect of atypical antipsychotic agents (Yüksel & Sayin, 2006) . Atypical antipsychotic agents bind to H1 receptors, which is an important parameter for weight gain. The more H1 affi nity increases, the more the sedation effect increases. Therefore, weight gain occurs because of increased appetite and decreased basal metabolism rate. In addition, 5-hydroxytryptamine (5-HT2C) 5-HT6 receptors and dopamine 2 (D 2 ) blockage are related to weight gain. D 2 blockage itself increases appetite, which causes individuals to eat more through the reward system (i.e., the neural circuitry of addiction and eating behavior [Adam & Epel, 2007] ) (Mizrahi et al., 2007) . Among adults, medications that cause the most weight gain are clozapine and olanzapine, whereas quetiapine and risperidone have a risk of mid-level weight gain (Çelik, Tahiroglu, & Avci, 2011) . Therefore, patients who were prescribed any of these antipsychotic agents were included in the current study. According to a previous meta-analysis, patients gained an average 3.8 kg in 3 weeks after they started taking atypical antipsychotic medications (Rummel-Kluge et al., 2010).
Aside from physical illnesses, such as hypertension and diabetes, which increase mortality because of weight gain, patients also encounter issues such as decreased self-respect, deformation of body image, breakdown in psychosocial functionality, and lack of exercise. Because of weight gain, patient quality of life is negatively affected. For patients who are overweight, in addition to stigmatization because of their mental disorders, a second possible stigmatization due to obesity may decrease treatment adherence (Demirel et al., 2015) . Moreover, dizziness, increases in sleep, insomnia, athetosis, constipation, and muscle contraction are other side effects that patients experienced in the current study.
When patients' number of daily meals were examined, most had three main meals per day and more than one half also had snacks. Bressington et al. (2013) found that 19% of patients diagnosed with mental disorders who attended mental health care services had three meals per day. It is possible that a higher rate was found in the current study because patients responded to this question by saying that they had three meals per day regularly or snacks during their hospitalization.
In the current study, although 31.7% of patients exercised daily, the duration of their exercise was short (mean duration = 7.74 minutes). Bressington et al. (2013) found in Hong Kong that 62% of patients exercised for <30 minutes fi ve times per week. In the current study, most patients who exercised stated that they exercised alone; 1.8% of patients exercised with mental health nurses at the hospital. Mental health nurses who are primarily responsible for the therapeutic environment can plan activities for patients during hospitalization (Ofl az, 2006) . To prevent weight gain side effects during hospitalization and encourage healthy behaviors, nurses can plan 30 minutes of exercise per day in the mornings. This activity can decrease the somnolence that patients have and motivate them for a good start to the day. In addition, patients must be informed that 30 minutes of exercises for at least 3 days per week can help them cope with the side effects of medications and protect their heart health.
In the current study, routine laboratory examinations conducted at the time of hospitalization were checked. The mean TC values were <200 mg/dL, LDL values were <130 mg/dL, HDL values were between 40 mg/dL and 60 mg/dL, TG values were <150 mg/dL, and FBG was <115 mg/dL. ALT, AST, and GGT liver enzymes were in the normal range, and the mean Cr value, which is a kidney function test, was <1.09 mg/dL (Çelik, Tahiroglu, & Avci, 2011) . Whether these values changed during patients' hospital stay could not be evaluated, as no tests were performed at discharge. These results may be in the acceptable range because the sample comprised young patients or as a result of the revolving door phenomenon: patients stop taking their medication and therefore have repeated hospitalizations, but the side effects do not occur because patients stopped taking the medication long before these repetitive hospital stays. Alternatively, the laboratory fi ndings may be in the normal range because patients eat less due to poor appetite, paranoid delusions, and thoughts in acute stages. Cerit, Ozten, and Yildiz (2008) found among outpatients in Turkey that the mean TG values were (CONTINUED)
137.64 mg/dL (SD = 105.4 mg/dL), mean HDL values were 42.08 mg/dL (SD = 11.16 mg/dL), and mean FBG values were 106.04 mg/dL (SD = 59.3 mg/dL). In the current study, similar results were found at the time of hospitalization. A signifi cant difference was found between physical measurements taken at the time of hospitalization and discharge. WCs, BMIs, DBPs, and HRs of patients increased, whereas no signifi cant difference was found between systolic blood pressure (SBP) values. Gaining weight, especially around the abdomen, is associated with insulin resistance, hyperlipidemia, and hypertension, which increase the risk for cardiovascular disorders (Demirel et al., 2015) . In the current study, atypical antipsychotic medications used for inpatient treatment increased the risk of cardiovascular disorders and negatively affected physical health. Bressington, Mui, Tse, et al. (2016) found that patients living in community mental health centers in Hong Kong had worse cardiometabolic health than the general population. In a study by Güveli et al. (2011) in Turkey, outpatients taking atypical antipsychotic medications were compared with a control group comprised of a healthy population with regard to metabolic syndrome, and it was found that DBP and SBP, WC, FBG, and TG values in the outpatient group were signifi cantly higher than in the control group.
Hardy, Hinks, and Gray (2013) compared the cardiovascular risks of patients diagnosed with diabetes and mental disorders in England and found that compared with patients with diabetes, patients with mental illness were not regularly assessed for cardiovascular risks and could not obtain the same services as patients with diabetes. Although patients with mental disorders are more at risk for cardiovascular events than the general population, there seem to be inequalities about obtaining physical health care services (Robson, Haddad, Gray, & Gournay, 2013) . Patients are at risk for cardiovascular illnesses due to medication side effects and unhealthy lifestyle conditions. These lifestyle conditions make it diffi cult to follow these patients. It is important that patients with mental disorders are followed regularly due to their increased physical health problems and informed about healthy habits. Therefore, psychiatrists should conduct regular scans for patients' physical health, and patients should be referred to internal disease specialists or cardiology specialists based on these scans. In addition, after hospital discharge, patients should be evaluated as a whole by the staff of their registered community mental health center and undergo follow-up examinations. Nurses should plan trainings for patients about healthy life habits, their illnesses, side effects from medications, and risky situations for their physical health. Kato, Currier, Gomez, Hall, and Gonzalez-Blanco (2004) assessed the physical characteristics of patients with schizophrenia and found that an increase in WC and a deterioration in the lipid profi le were observed frequently. These measurements were the most important parameters for the assessment of metabolic syndrome and should be monitored carefully (Kato et al., 2004 ).
In the current study, female participants' WCs were >88 cm at hospitalization and discharge. These values were higher than the normal WC limit stated in the metabolic syndrome defi nition by the International Diabetes Foundation (2006) and determined as the WC limit for Turkish women by the Turkish Republic Ministry of Health, Department of Obesity, Diabetes, and Metabolic Illnesses. For male participants, mean WC was <94 cm, which is acceptable as the WC limit for Turkish men. Cerit, Oztem, and Yildiz (2008) found in their study in Turkey that the WCs of outpatients were 97.69 cm (SD = 13.03 cm) for men and 94.26 cm (SD = 14.04 cm) for women, both of which exceeded the normal limit. WC is itself an important determinant for metabolic syndrome and central obesity is a risk for heart health (Kaya et al., 2009) . Compared with male patients, female patients gain more weight and are more at risk for metabolic syndrome because of atypical antipsychotic medication use (Demirel et al., 2015; Songur et al., 2012) . Bressington et al. (2013) found that 32% of female patients and 61% of male patients in their sample had WCs above the normal limits in China. According to data collected in the current study, female inpatients in Turkey have more cardiovascular risk than outpatients in China. Cerit et al. (2008) found that female patients with schizophrenia have higher metabolic syndrome risks. The metabolic status of patients should be checked, particularly when risk factors such as old age, being female, long duration of disease and treatment, and family history of obesity are in question (Cerit et al., 2008 ).
In the current study, patients' BMIs were higher than normal at the time of hospitalization. In the study by Öyekçin (2009) , BMIs of patients with schizophrenia and schizoaffective disorder were also higher than normal. Unhealthy eating habits and metabolic side effects from medications before patient hospitalization may cause high BMIs. A study in Turkey of outpatients with schizophrenia found WCs and BMIs of these patients were higher than in a control group comprised of individuals without schizophrenia (Demirel et al., 2013) . In a study performed in Taiwan, cardiovascular profi les and BMI values of patients with mental illness were found to be better than expected and researchers stated that this was related to patient lifestyle and eating habits (Thongsai, Gray, & Bressington, 2016) . In view of Turkish society, consumption of more fatty foods in Turkish cuisine, poor socioeconomic conditions, and preferences for fast food, which are carbohydraterich and can be consumed quickly (Eraslan, Öztürk, Kayahan, Zorlu, & Veznedaroglu, 2006) , are thought to be the main reasons for high BMIs.
STUDY LIMITATIONS AND STRENGTHS
The limitations of the current study include not being able to generalize the fi ndings because the research was performed at only one hospital and contained a small patient population; laboratory values were not reexamined at discharge; and information regarding diabetes, hypertension, dyslipidemia, and smoking habits in patients' family histories was unknown. Hospitalization is a sedentary process that may cause weight gain, but a separate assessment or measurement could not be performed for this potential weight gain. In addition, there was no control group comprising individuals who were not using atypical antipsychotic medications.
Strengths of the current study include: data were collected by a single researcher, circumference measurement tools were used, patients took their medications regularly during hospitalization, and the results were not retrospective.
RELEVANCE TO CLINICAL PRACTICE
The current study contributes to the existing literature on metabolic side effects of patients who take atypical antipsychotic medications during hospitalization. According to the results, patients experience some metabolic side effects during hospitalization due to treatment with atypical antipsychotic medications. Mental health nurses should inform patients of medication effects and possible side effects, evaluate patients' adherence to treatment and causes of nonadherence if they have diffi culty complying with treatment, monitor side effects, and teach patients how to manage metabolic side effects. Nurses should focus on not only mental disorders but also the physical health of patients who take atypical antipsychotic medications.
CONCLUSION
Metabolic side effects from atypical antipsychotic medications were evaluated in a group of inpatients with mental disorders, with a statistically signifi cant difference found between patient hospitalization and discharge values for WC, BMI, DBP, and HR. Patients gained weight, which increased their risk for cardiovascular illnesses and negatively affected their physical health.
Antipsychotic agents are used to help reduce the number of episodes and hospitalizations due to the severity of mental illness symptoms. These medications keep disability at a minimum as well as reduce the violence of an individual toward him/ herself and the environment. Regular use of these medications is the most important treatment goal for patients and health care staff. Determination and elimination of medication side effects, prevention of nonadherence to treatment, and determination and elimination of the factors that cause nonadherence are the responsibilities of mental health staff. Mental health nurses should administer medications and inform patients and their relatives about possible side effects. Mental health nurses should follow the effects and symptoms from the medications and share possible side effects with psychiatrists. To assess and communicate these side effects, nurses must use standard measurement tools prepared to observe side effects and physical health. In addition, nurses should teach patients how to cope with metabolic side effects that negatively affect physical health. Patients with weight gain side effects must be educated about behavioral changes, such as having snacks, minimizing portions, exercising for 30 minutes at least 3 days per week, and choosing low-calorie foods. Nurses can organize individual or group psychoeducation for inpatients about medication therapy and its side effects.
